Overview

Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

Status:
Withdrawn

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.

Phase:

N/A

Details

Lead Sponsor:

Institute of Liver and Biliary Sciences, India

Treatments:

Adrenergic beta-Antagonists
Carvedilol